Breast CancerJOUVENCENCT07425548
Evaluation of Quality of Life After Facial Hyaluroic Acid Injections Following Treatment for Breast Cancer.
A study testing Inject of hyaluronic acid in the face in people with Breast Cancer and Aesthetic Improvement of the Skin, run by Institut Bergonié.
Trial summary
Breast cancer, the most common cancer in women, is increasingly managed as a chronic disease thanks to therapeutic advances. However, treatments such as chemotherapy and hormonotherapy often induce premature menopause in younger women, leading to skin aging, atrophy, and distressing symptoms that negatively affect… Read more about this study
- Who is it for?
- Ages 18 to 50 years, women only
- Conditions the study is for
- Breast Cancer, Aesthetic Improvement of the Skin
- What is being tested?
- Inject of hyaluronic acid in the face
- Type of treatment
- Injection or infusion, Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 22 participants
- Where
- No sites listed yet
- Study dates
- Apr 2026to Sep 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 50 years
- Women only
- No healthy volunteers
- Adult
Who may be able to join
- Women ≥ 18 years old and ≤ 50 years old.
- Non-menopausal status at time of diagnosis of breast cancer (self-reporting).
- Patient with breast cancer (uni or bilateral):
- treated at the Institut Bergonié by chemotherapy (+/- targeted/immunotherapy) and surgical treatment (conservative or not) and/or hormone therapy and/or radiotherapy
- who completed their treatment at least 6 months ago including end of treatment with Herceptin but with the exception for ongoing hormone therapy
- in complete remission
Show all 9Show fewer
- Non-immunosuppressed patient.
- Voluntarily signed and dated written informed consent prior to any study specific procedure.
- Patient affiliated to a social security in compliance with Article 1121-11 of the French Public Health Code.
Who cannot join
- Patients with a history of or declared autoimmune disease or immune system deficiency or undergoing immunosuppressive treatment. A 6-month washout is required.
- Patients undergoing or planning to undergo peeling treatment or laser/ultrasound-based or botox treatment or hyaluronic acid injections during the study or having had one of these treatments in the 6 months preceding the study.
- Patients showing cutaneous disorders, inflammation or infection (acne, herpes labialis, scars…) at the treatment site or near to this site.
- Patients having a known hypersensibility to lidocaine and/or amide local anaesthetic agents or hyaluronic acid and/or proteins from gram-positive bacteria, or with a history of severe allergy or anaphylactic shock.
- Patients with a history of streptococcal disease (recurrent sore throat, rheumatic fever)
- Patients with autoimmune or cardiac diseases (i.e. heart conduction disorders) and/or undergoing treatment for heart diseases (beta-blockers).
Show all 14Show fewer
- Patients with hepatocellular insufficiency and/or undergoing treatment for liver disease.
- Patients suffering from epilepsy not controlled by a treatment or porphyria.
- Patients with a tendency to develop hypertrophic scars.
- Patients with severe, ongoing and/or uncontrolled disease that may pose a health risk to the patient during the study and/or may have an impact on the study assessments.
- Patients receiving or planning to receive high dose Vitamin E, aspirin, anti-inflammatories, or anti-coagulant during the week preceding each injection
- Patients receiving any long-term medical treatment or any treatment that, in the opinion of the clinical investigator, may interfere with test results or put the patient at undue risk.
- Patients under guardianship/tutorship.
- Pregnant women or breastfeeding mothers.
About this study
Breast cancer, the most common cancer in women, is increasingly managed as a chronic disease thanks to therapeutic advances. However, treatments such as chemotherapy and hormonotherapy often induce premature menopause in younger women, leading to skin aging, atrophy, and distressing symptoms that negatively affect quality of life. These cutaneous effects are frequently overlooked despite their psychological and social impact. Hyaluronic acid injections, already well established in aesthetic and reconstructive medicine, may offer a safe, minimally invasive option to restore skin quality, improve self-esteem, and enhance overall well-being in breast cancer survivors. This study aims to assess their efficacy and safety in this specific population.
- Conditions
- Breast Cancer, Aesthetic Improvement of the Skin
- Being tested
- Inject of hyaluronic acid in the face
- Medical subject headings
- Breast Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Inject of hyaluronic acid in the faceDevice
The patient may receive up to 1 ml (volume of one syringe) of each of the three HA references (between 1 ml and 3 ml maximum). The HA reference(s) to be injected will be chosen on the basis of the investigator's assessment and the patient's desired correction.
| Study group | Role | What they receive |
|---|---|---|
| Hyaluronic acid injection | Other | Not described Receives: Device: Inject of hyaluronic acid in the face |
What is being measured
The primary outcome is the main question the study is designed to answer.
Facial appearance following facial hyaluronic acid injection following breast cancer treatment.
Facial appearance will be measured using the score obtained at the "facial appearance" subdomain of the FACE-Q Aesthetics Questionnaire. The score ranges from 0 (worst outcome) to 100 (best outcome).
Measured: 3 months
Health-related quality of life followig facial hyaluronic acid injection following breast cancer treatment.
Health-related quality of life will be measured using the score obtained at the "health-related quality of life" subdomain of the FACE-Q Aesthetics Questionnaire. The score ranges from 0 (worst outcome) to 100 (best outcome).
Measured: 3 months
Adverse effects following facial hyaluronic acid injection following breast cancer treatment.
Adverse effects will be measured using the score obtained at the "Adverse effects" subdomain of the FACE-Q Aesthetics Questionnaire. The score ranges from 0 (worst outcome) to 100 (best outcome).
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Feb 2026
- Study startApr 2026 (estimated)
- Primary completionJul 2027 (estimated)
- Study completionSep 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Breast CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 22 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Institut Bergonié
- Sponsor type
- University, hospital or other
- Collaborators
- Ruban Rose
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07425548
- Sponsor's protocol ID
- IB 2025-01
- Acronym
- JOUVENCE
- Status last verified
- Apr 2026
- First submitted
- 16 Feb 2026
- Last updated
- 16 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of Quality of Life After Facial Hyaluroic Acid Injections Following Treatment for Breast Cancer.
- ClinicalTrials.gov ID
- NCT07425548
- Acronym / sponsor ID
- JOUVENCE / IB 2025-01
- Conditions
- Breast Cancer, Aesthetic Improvement of the Skin
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 22 participants (estimated)
- Lead sponsor
- Institut BergoniéUniversity, hospital or other
- Collaborators
- Ruban Rose
- Study start
- Apr 2026 (estimated)
- Primary completion
- Jul 2027 (estimated)
- Study completion
- Sep 2027 (estimated)
- First posted
- 23 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Breast cancer, the most common cancer in women, is increasingly managed as a chronic disease thanks to therapeutic advances. However, treatments such as chemotherapy and hormonotherapy often induce premature menopause in younger women, leading to skin aging, atrophy, and distressing symptoms that negatively affect quality of life. These cutaneous effects are frequently overlooked despite their psychological and social impact. Hyaluronic acid injections, already well established in aesthetic and reconstructive medicine, may offer a safe, minimally invasive option to restore skin quality, improve self-esteem, and enhance overall well-being in breast cancer survivors. This study aims to assess their efficacy and safety in this specific population.
Study design
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Hyaluronic acid injection | Other | Device: Inject of hyaluronic acid in the face |
Who may qualify
- Ages
- 18 to 50 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (9 listed)
- Women ≥ 18 years old and ≤ 50 years old.
- Non-menopausal status at time of diagnosis of breast cancer (self-reporting).
- Patient with breast cancer (uni or bilateral):
- Non-immunosuppressed patient.
- Voluntarily signed and dated written informed consent prior to any study specific procedure.
Key exclusion criteria (14 listed)
- Patients with a history of or declared autoimmune disease or immune system deficiency or undergoing immunosuppressive treatment. A 6-month washout is required.
- Patients undergoing or planning to undergo peeling treatment or laser/ultrasound-based or botox treatment or hyaluronic acid injections during the study or having had one of these treatments in the 6 months preceding the study.
- Patients showing cutaneous disorders, inflammation or infection (acne, herpes labialis, scars…) at the treatment site or near to this site.
- Patients having a known hypersensibility to lidocaine and/or amide local anaesthetic agents or hyaluronic acid and/or proteins from gram-positive bacteria, or with a history of severe allergy or anaphylactic shock.
- Patients with a history of streptococcal disease (recurrent sore throat, rheumatic fever)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Inject of hyaluronic acid in the faceThe patient may receive up to 1 ml (volume of one syringe) of each of the three HA references (between 1 ml and 3 ml maximum). The HA reference(s) to be injected will be chosen on the basis of the investigator's assessment and the patient's desired correction. | Device | Hyaluronic acid injection |
Primary outcome
Facial appearance following facial hyaluronic acid injection following breast cancer treatment.
Time frame: 3 months
Facial appearance will be measured using the score obtained at the "facial appearance" subdomain of the FACE-Q Aesthetics Questionnaire. The score ranges from 0 (worst outcome) to 100 (best outcome).
Health-related quality of life followig facial hyaluronic acid injection following breast cancer treatment.
Time frame: 3 months
Health-related quality of life will be measured using the score obtained at the "health-related quality of life" subdomain of the FACE-Q Aesthetics Questionnaire. The score ranges from 0 (worst outcome) to 100 (best outcome).
Adverse effects following facial hyaluronic acid injection following breast cancer treatment.
Time frame: 3 months
Adverse effects will be measured using the score obtained at the "Adverse effects" subdomain of the FACE-Q Aesthetics Questionnaire. The score ranges from 0 (worst outcome) to 100 (best outcome).
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Apr 2026.
Related trials for Breast Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 2
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Invasive Mammary Carcinoma, Metastatic Breast Cancer
Not yet recruitingObservational study
Comparison of Reliability, Time Cost, and Participant Comfort of Lymphedema Assessments in Upper Extremity
Lymphedema, Upper Extremity Lymphedema
RecruitingPhase 3
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
TNBC - Triple-Negative Breast Cancer
RecruitingPhase 3
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A study testing Inject of hyaluronic acid in the face in people with Breast Cancer and Aesthetic Improvement of the Skin, run by Institut Bergonié.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 16 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Facial appearance following facial hyaluronic acid injection following breast cancer treatment. (time frame: 3 months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Apr 2026.